Key Milestones

The targeted concentration effect and reversibility of
plaque formation were discovered through early lab studies.

Beijing Inno Medicine Co. Ltd. was incorporated.
An in-house R&D team was established and awarded
funds by NSFC and Beijing Science and Technology Commission.

A pilot plant was set up.
Technology transfer from Anzhen Hospital was completed.
Round Pre-A fundraising done with Beijing Science and Technology Investment Group.

Inno Med was moved to Haidian R&D Center.

Formulation YN001 was finalized and scaled up at the pilot plant.
RMB 200 million was raised in Round A.

YN001 obtained FDA IND approval;
Initiated Phase I clinical trial in Australia;
Commenced construction of the first GMP production line at the Shanghai facility.

YN001 obtained NMPA IND approval;
Completed YN001 Phase Ia clinical trial and initiated Phase Ib/IIa trial;
Series B financing of RMB 500 million;
Construction of the Shanghai GMP facility completed with the first production line.